Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brimonidine tartrate/carbachol - Tenpoint Therapeutics

Next Previous
Drug Profile

Brimonidine tartrate/carbachol - Tenpoint Therapeutics

Alternative Names: BRIMOCHOL; BRIMOCHOL PF™; BRIMOCHOL™ F; VT-1011; VTI-001; YUVEZZI

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Visus Therapeutics
  • Developer Tenpoint Therapeutics; Zhaoke Ophthalmology Limited
  • Class Amines; Antiglaucomas; Antihypertensives; Carbamates; Ethanolamines; Eye disorder therapies; Imidazoles; Miotics; Quinoxalines; Skin disorder therapies; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Cholinergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Presbyopia

Most Recent Events

  • 28 Mar 2026 Launched for Presbyopia in USA (Ophthalmic)
  • 28 Jan 2026 Registered for Presbyopia in USA (Ophthalmic) (Tenpoint Therapeutics pipeline, March 2026)
  • 05 Nov 2025 Preregistration for Presbyopia in South Korea (Ophthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top